2025年11月27日,中国生物医药领域传来重磅消息:绿叶制药集团控股子公司博安生物自主研发的博优景(阿柏西普眼内注射溶液)正式获得国家药品监督管理局上市批准。这款用于治疗新生血管(湿性)年龄相关性黄斑变性(nAMD)和糖尿病性黄斑水肿(DME)的生物类似药,不仅为千万眼底病患者带来了治疗新选择,更标志着我国生物类似药研发又买入新阶段。眼底疾病已成为我国致盲的主要原因之一,其中nAMD和DME尤为...
Source Link2025年11月27日,中国生物医药领域传来重磅消息:绿叶制药集团控股子公司博安生物自主研发的博优景(阿柏西普眼内注射溶液)正式获得国家药品监督管理局上市批准。这款用于治疗新生血管(湿性)年龄相关性黄斑变性(nAMD)和糖尿病性黄斑水肿(DME)的生物类似药,不仅为千万眼底病患者带来了治疗新选择,更标志着我国生物类似药研发又买入新阶段。眼底疾病已成为我国致盲的主要原因之一,其中nAMD和DME尤为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.